Tissue Factor in Tumor Microenvironment: a Systematic Review

Overview

Journal J Hematol Oncol

Publisher Biomed Central

Specialties Hematology
Oncology

Date 2014 Aug 3

PMID 25084809

Citations 49

Authors

Xiao Han

Bo Guo

Yongsheng Li

Bo Zhu

Affiliations

Soon will be listed here.

Abstract

The aberrant hemostasis is a common manifestation of cancer, and venous thromboembolism (VTE) is the second leading cause of cancer patients' mortality. Tissue factor (TF), comprising of a 47-kDa transmembrane protein that presents in subendothelial tissues and leukocytes and a soluble isoform, have distinct roles in the initiation of extrinsic coagulation cascade and thrombosis. Laboratory and clinical evidence showed the deviant expression of TF in several cancer systems and its tumor-promoting effects. TF contributes to myeloid cell recruitment in tumor stroma, thereby remodeling of tumor microenvironment. Additionally, the number of TF-positive-microparticles (TF+MP) from tumor origins correlates with the VTE rates in cancer patients. In this review, we summarize our current understanding of the TF regulation and roles in tumor progression and clinical complications.

Citing Articles

Tissue factor targeted near-infrared photoimmunotherapy: a versatile therapeutic approach for malignancies.

Takao S, Fukushima H, Furusawa A, Kato T, Okuyama S, Kano M Cancer Immunol Immunother. 2025; 74(2):48.

PMID: 39751657 PMC: 11699179. DOI: 10.1007/s00262-024-03903-2.

O-GlcNAcylation: Crosstalk between Hemostasis, Inflammation, and Cancer.

Vasquez Martinez I, Perez-Campos E, Perez-Campos Mayoral L, Cruz Luis H, Pina Canseco M, Zenteno E Int J Mol Sci. 2024; 25(18).

PMID: 39337387 PMC: 11432004. DOI: 10.3390/ijms25189896.

Effectiveness and Safety of the Traditional Chinese Medicine Treatment ( Therapy) for Malignant Tumors: A Systematic Review and Meta-Analysis.

Chen Z, Wang A, Wei Y, Zhu Y, An J, Li Z Evid Based Complement Alternat Med. 2023; 2022:7944063.

PMID: 38094221 PMC: 10718885. DOI: 10.1155/2022/7944063.

An idiosyncratic zonated stroma encapsulates desmoplastic liver metastases and originates from injured liver.

Moro C, Geyer N, Harrizi S, Hamidi Y, Soderqvist S, Kuznyecov D Nat Commun. 2023; 14(1):5024.

PMID: 37596278 PMC: 10439160. DOI: 10.1038/s41467-023-40688-x.

Amygdalin-folic acid-nanoparticles inhibit the proliferation of breast cancer and enhance the effect of radiotherapy through the modulation of tumor-promoting factors/ immunosuppressive modulators in vitro.

Askar M, El-Sayyad G, Guida M, Khalifa E, Shabana E, Abdelrahman I BMC Complement Med Ther. 2023; 23(1):162.

PMID: 37210478 PMC: 10199568. DOI: 10.1186/s12906-023-03986-x.

References

Srinivasan R, Bogdanov V . Alternatively spliced tissue factor: discovery, insights, clinical implications. Front Biosci (Landmark Ed). 2011; 16(8):3061-71. DOI: 10.2741/3899. View

van den Berg Y, Osanto S, Reitsma P, Versteeg H . The relationship between tissue factor and cancer progression: insights from bench and bedside. Blood. 2011; 119(4):924-32. DOI: 10.1182/blood-2011-06-317685. View

Schaffner F, Yokota N, Ruf W . Tissue factor proangiogenic signaling in cancer progression. Thromb Res. 2012; 129 Suppl 1:S127-31. DOI: 10.1016/S0049-3848(12)70032-4. View

Contrino J, Hair G, Kreutzer D, Rickles F . In situ detection of tissue factor in vascular endothelial cells: correlation with the malignant phenotype of human breast disease. Nat Med. 1996; 2(2):209-15. DOI: 10.1038/nm0296-209. View

Yu G, Li H, Wang X, Wu T, Zhu J, Huang S . MicroRNA-19a targets tissue factor to inhibit colon cancer cells migration and invasion. Mol Cell Biochem. 2013; 380(1-2):239-47. DOI: 10.1007/s11010-013-1679-6. View

Hong H, Zhang Y, Nayak T, Engle J, Wong H, Liu B . Immuno-PET of tissue factor in pancreatic cancer. J Nucl Med. 2012; 53(11):1748-54. PMC: 3489969. DOI: 10.2967/jnumed.112.105460. View

Pabinger I, Thaler J, Ay C . Biomarkers for prediction of venous thromboembolism in cancer. Blood. 2013; 122(12):2011-8. DOI: 10.1182/blood-2013-04-460147. View

Signaevsky M, Hobbs J, Doll J, Liu N, Soff G . Role of alternatively spliced tissue factor in pancreatic cancer growth and angiogenesis. Semin Thromb Hemost. 2008; 34(2):161-9. DOI: 10.1055/s-2008-1079256. View

Amirkhosravi A, Meyer T, Chang J, Amaya M, Siddiqui F, Desai H . Tissue factor pathway inhibitor reduces experimental lung metastasis of B16 melanoma. Thromb Haemost. 2002; 87(6):930-6. View

10.

Saito Y, Hashimoto Y, Kuroda J, Yasunaga M, Koga Y, Takahashi A . The inhibition of pancreatic cancer invasion-metastasis cascade in both cellular signal and blood coagulation cascade of tissue factor by its neutralisation antibody. Eur J Cancer. 2011; 47(14):2230-9. DOI: 10.1016/j.ejca.2011.04.028. View

11.

Aberg M, Johnell M, Wickstrom M, Siegbahn A . Tissue Factor/ FVIIa prevents the extrinsic pathway of apoptosis by regulation of the tumor suppressor Death-Associated Protein Kinase 1 (DAPK1). Thromb Res. 2010; 127(2):141-8. DOI: 10.1016/j.thromres.2010.11.015. View

12.

Magnus N, Garnier D, Rak J . Oncogenic epidermal growth factor receptor up-regulates multiple elements of the tissue factor signaling pathway in human glioma cells. Blood. 2010; 116(5):815-8. DOI: 10.1182/blood-2009-10-250639. View

13.

Muller M, Albrecht S, Golfert F, Hofer A, Funk R, Magdolen V . Localization of tissue factor in actin-filament-rich membrane areas of epithelial cells. Exp Cell Res. 1999; 248(1):136-47. DOI: 10.1006/excr.1999.4395. View

14.

Szotowski B, Antoniak S, Poller W, Schultheiss H, Rauch U . Procoagulant soluble tissue factor is released from endothelial cells in response to inflammatory cytokines. Circ Res. 2005; 96(12):1233-9. DOI: 10.1161/01.RES.0000171805.24799.fa. View

15.

Bogdanov V, Balasubramanian V, Hathcock J, Vele O, Lieb M, Nemerson Y . Alternatively spliced human tissue factor: a circulating, soluble, thrombogenic protein. Nat Med. 2003; 9(4):458-62. DOI: 10.1038/nm841. View

16.

Kocaturk B, van den Berg Y, Tieken C, Mieog J, de Kruijf E, Engels C . Alternatively spliced tissue factor promotes breast cancer growth in a β1 integrin-dependent manner. Proc Natl Acad Sci U S A. 2013; 110(28):11517-22. PMC: 3710867. DOI: 10.1073/pnas.1307100110. View

17.

Rong Y, Belozerov V, Tucker-Burden C, Chen G, Durden D, Olson J . Epidermal growth factor receptor and PTEN modulate tissue factor expression in glioblastoma through JunD/activator protein-1 transcriptional activity. Cancer Res. 2009; 69(6):2540-9. PMC: 2759716. DOI: 10.1158/0008-5472.CAN-08-1547. View

18.

Falanga A, Russo L . Epidemiology, risk and outcomes of venous thromboembolism in cancer. Hamostaseologie. 2011; 32(2):115-25. DOI: 10.5482/ha-1170. View

19.

Thaler J, Ay C, Mackman N, Metz-Schimmerl S, Stift J, Kaider A . Microparticle-associated tissue factor activity in patients with pancreatic cancer: correlation with clinicopathological features. Eur J Clin Invest. 2013; 43(3):277-85. DOI: 10.1111/eci.12042. View

20.

Vrana J, Stang M, Grande J, Getz M . Expression of tissue factor in tumor stroma correlates with progression to invasive human breast cancer: paracrine regulation by carcinoma cell-derived members of the transforming growth factor beta family. Cancer Res. 1996; 56(21):5063-70. View